🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Amphastar Pharmaceuticals, Inc. AMPH R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

READ MORE ›
$18.85
-26.68% 1Y

Market & Price

Market Cap
$831.15M
Current Price
$18.85
High / Low (52W)
$30.81 / $16.87
Beta
0.97

Valuation

Stock P/E
11.36
Industry PE
23.65
Forward P/E
5.75
PEG Ratio
-
Book Value
$17.33
Price to Book
1.09
P/S
1.15
EV/EBITDA
6.21
Dividend Yield
-

Profitability & Returns

ROCE
10.14%
ROE
10.39%
ROA
5.34%
Profit Margin
11.00%
Op Margin
7.96%
EPS (Latest Qtr)
$0.14
EPS (TTM)
$1.66

Balance Sheet & Liquidity

Debt/Equity
0.89
Quick Ratio
2.73
Current Ratio
3.85
Debt
$686.38M
Total Assets
$1.63B
Current Assets
$636.02M
Working Capital
$477.86M

Ownership

Promoter Holding
29.63%
Chg in Prom Hold
0.29%
FII / Inst Holding
76.38%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$1.23B
Total Revenue (TTM)
$720.53M
EBITDA
$197.27M
Free Cash Flow
$103.10M
Operating Cash Flow
$168.88M
Shares Outstanding
44.09M
Gross Margin
47.34%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
12.99%
Profit 5Y
2.39%
Revenue (YoY)
0.40%
Earnings (YoY)
-72.50%

PROS

  • Compounding revenue at 13.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 38.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMPH Amphastar Pharmaceuticals, Inc. R2K 18.85 11.36 $831.15M - 10.14% 10.39% 12.99% 2.39%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------56.67M65.19M57.92M60.40M58.39M71.04M75.54M89.69M79.79M79.05M80.14M83.38M84.69M85.81M83.43M103.02M101.66M112.20M120.37M123.47M120.13M140.02M145.71M180.56M171.84M182.39M191.21M-170.53M174.41M191.84M183.10M171.17M
Cost of Revenue -----------------------------------85.28M87.92M93.19M97.44M100.85M
Gross Profit 13.32M17.58M33.17M24.90M31.71M27.61M19.96M22.81M26.66M20.55M20.49M16.97M26.06M29.26M34.69M30.90M32.39M35.25M33.38M36.82M33.18M36.51M44.95M47.38M51.18M55.83M63.36M58.51M73.84M72.74M108.40M90.10M95.17M101.94M-85.25M86.49M98.65M85.67M70.32M
Operating Expenses -----------------------------------47.96M44.31M73.33M50.06M56.69M
Operating Income -10.26M-3.75M-4.08M10.33M5.80M-1.40M2.19M-2.94M--9.78M-2.94M2.55M--3.17M973.00K2.40M-7.48M-2.92M3.52M10.31M10.56M24.77M21.61M24.82M23.23M33.43M36.90M72.68M48.01M55.22M57.05M-37.29M42.18M25.32M35.61M13.63M
EBITDA -----------------------------------52.35M61.85M43.56M54.53M33.10M
Interest Expense -----------------------------------6.29M6.28M6.28M6.63M6.55M
Pretax Income -----------------------------------30.86M39.34M21.51M31.91M10.05M
Tax Provision -----------------------------------5.58M8.30M4.16M7.49M3.63M
Net Income -6.65M-3.01M7.53M2.49M6.89M3.89M-2.74M893.00K1.97M99.00K1.47M-7.14M-2.85M2.39M1.87M868.00K47.79M1.31M-1.03M3.95M-192.00K3.92M5.04M7.77M29.55M24.25M17.35M15.87M26.03M26.12M49.22M43.18M37.95M40.43M-25.29M31.03M17.35M24.43M6.42M
Diluted EPS -0.15-0.070.160.050.150.08-0.060.020.040.000.02-0.15-0.060.050.040.020.960.03-0.020.080.000.080.100.160.590.470.330.300.500.490.910.810.730.78-0.510.640.370.510.14
R&D Expense 10.73M11.12M-8.61M10.59M9.72M-11.25M10.73M10.07M-14.03M15.46M11.34M-14.61M16.00M18.61M-15.30M16.15M17.64M14.77M18.12M10.76M16.22M22.80M18.51M19.82M16.84M16.66M17.04M17.65M21.08M-20.10M20.08M22.35M-26.74M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ----255.16M240.18M294.67M322.36M349.85M-498.99M644.39M731.97M719.89M
Cost of Revenue ----------250.13M293.27M358.11M363.83M
Gross Profit 90.30M86.96M51.26M77.35M104.20M90.51M106.98M131.92M143.34M-248.86M351.12M373.86M356.06M
Operating Expenses ----------141.36M154.13M168.44M215.65M
Operating Income 25.40M17.49M-17.98M-6.90M15.38M-1.27M-8.62M-39.00K10.95M-107.50M196.99M205.42M140.40M
EBITDA ----------146.16M240.29M277.31M212.31M
Interest Expense ----------1.85M27.16M30.34M25.48M
Pretax Income ----------116.04M171.36M189.76M123.62M
Tax Provision ----------23.48M31.83M29.67M25.53M
Net Income 18.09M11.86M-10.70M-2.79M9.82M3.65M-5.74M48.94M1.40M-91.39M137.54M159.52M98.09M
Diluted EPS 0.460.31-0.25-0.060.210.08-0.120.980.03-1.742.603.062.03
R&D Expense 31.16M33.02M28.87M37.27M41.52M43.50M57.56M68.85M67.23M60.93M74.77M73.74M73.91M85.84M

Compounded Sales Growth

5 Years:12.99%
1 Year:0.40%

Compounded Profit Growth

5 Years:2.39%
1 Year:-72.50%

Stock Price Performance

1 Year:-26.68%
6 Months:-31.92%
3 Months:-6.82%
1 Month:-12.85%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --338.75M389.37M390.14M427.74M451.07M513.56M586.97M631.24M-741.99M1.51B1.58B1.63B
Current Assets -----------378.32M489.60M534.07M636.02M
Cash & Equivalents 53.74M50.21M53.59M67.83M66.07M72.35M65.59M86.34M73.69M92.64M-156.10M144.30M151.61M170.18M
Inventory -----------103.58M105.83M153.74M176.89M
Receivables -----------88.80M114.94M136.29M143.56M
Total Liabilities --87.20M107.51M94.63M98.48M117.34M149.20M159.44M182.51M-213.33M873.49M845.17M840.49M
Current Liabilities --65.40M62.59M59.95M60.62M67.19M106.83M90.01M112.20M-94.86M225.41M173.76M158.16M
Long Term Debt ---42.68M40.30M36.03M45.72M49.10M46.32M45.92M-72.84M589.58M601.63M608.75M
Total Debt -----------102.58M623.64M650.55M656.00M
Total Equity 208.52M233.44M251.54M281.86M295.51M329.25M333.74M332.44M381.37M402.31M-528.66M639.42M732.30M788.80M
Shares Outstanding -----------58.11M59.39M60.85M61.78M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---10.68M38.56M39.21M38.19M41.76M57.27M-89.18M183.50M213.39M156.12M
Investing Cash Flow ----16.93M-39.50M-36.89M-42.18M-50.53M-36.41M--32.78M-649.12M-124.93M-70.33M
Financing Cash Flow ---2.24M7.14M-7.72M25.01M-3.78M-2.25M--26.44M454.09M-80.95M-67.42M
Capital Expenditure -23.13M-17.64M-20.50M-16.00M-21.38M-35.10M-46.81M-41.55M-33.85M--24.03M-38.17M-41.04M-37.13M
Free Cash Flow ----5.32M17.18M4.11M-8.62M207.00K23.41M-65.15M145.34M172.34M118.98M
Net Change in Cash ----------29.96M-11.52M7.50M18.36M
Share Buybacks 811.00K199.00K345.00K9.87M9.91M30.75M25.05M22.29M24.43M28.87M39.91M58.14M85.46M75.59M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----40.8%37.7%36.3%40.9%41.0%-49.9%54.5%51.1%49.5%
Operating Margin % ----6.0%-0.5%-2.9%-0.0%3.1%-21.5%30.6%28.1%19.5%
Net Margin % ----3.8%1.5%-1.9%15.2%0.4%-18.3%21.3%21.8%13.6%
ROE % 7.8%4.7%-3.8%-0.9%3.0%1.1%-1.7%12.8%0.3%-17.3%21.5%21.8%12.4%
ROCE % -6.4%-5.5%-2.1%4.2%-0.3%-2.1%-0.0%2.1%-16.6%15.3%14.6%9.5%

Shareholding Pattern

Insiders
29.63%
Institutions
76.38%
Public Float
108.54%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.30% 5.42M $102.19M
2 Dimensional Fund Advisors LP 4.60% 2.03M $38.23M
3 State Street Corporation 3.65% 1.61M $30.30M
4 Vanguard Capital Management LLC 3.50% 1.54M $29.10M
5 TD Asset Management, Inc 3.49% 1.54M $29.05M
6 Fuller & Thaler Asset Management Inc. 3.16% 1.40M $26.30M
7 Marshall Wace LLP 2.33% 1.03M $19.33M
8 American Century Companies Inc 2.31% 1.02M $19.18M
9 Geode Capital Management, LLC 2.21% 976.65K $18.41M
10 Boston Trust Walden Corporation 2.14% 944.79K $17.81M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMPH

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks